Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
31.39
+1.42 (4.74%)
At close: Apr 14, 2026, 4:00 PM EDT
31.39
0.00 (0.00%)
After-hours: Apr 14, 2026, 4:10 PM EDT
Rigel Pharmaceuticals Employees
As of December 31, 2025, Rigel Pharmaceuticals had 174 total employees, including 172 full-time and 2 part-time employees. The number of employees increased by 10 or 6.10% compared to the previous year.
Employees
174
Change (1Y)
10
Growth (1Y)
6.10%
Revenue / Employee
$1,691,276
Profits / Employee
$2,109,333
Market Cap
579.87M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 174 | 10 | 6.10% | 172 | 2 |
| Dec 31, 2024 | 164 | 17 | 11.56% | 162 | 2 |
| Dec 31, 2023 | 147 | -8 | -5.16% | 147 | 0 |
| Dec 31, 2022 | 155 | -10 | -6.06% | 155 | 0 |
| Dec 31, 2021 | 165 | -4 | -2.37% | 165 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Valneva SE | 674 |
| Lyell Immunopharma | 300 |
| CorMedix | 191 |
| Kyverna Therapeutics | 130 |
| Upstream Bio | 75 |
| Aclaris Therapeutics | 73 |
| Prothena Corporation | 67 |
RIGL News
- 7 days ago - Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 14 days ago - Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology - PRNewsWire
- 5 weeks ago - Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - PRNewsWire
- 7 weeks ago - Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update - PRNewsWire
- 2 months ago - Rigel Appoints Michael P. Miller to the Board of Directors - PRNewsWire
- 3 months ago - Rigel Provides Business Update and 2026 Outlook - PRNewsWire
- 3 months ago - Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 4 months ago - Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition - PRNewsWire